Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-22-066277
Filing Date
2022-03-04
Accepted
2022-03-04 17:03:32
Documents
4

Document Format Files

Seq Description Document Type Size
1 424B5 d251573d424b5.htm 424B5 460093
2 EX-FILING FEES d251573dexfilingfees.htm EX-FILING FEES 25251
3 GRAPHIC g251573g01a17.jpg GRAPHIC 30008
4 GRAPHIC g251573g60d80.jpg GRAPHIC 28932
  Complete submission text file 0001193125-22-066277.txt   561338
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-251022 | Film No.: 22715077
SIC: 2835 In Vitro & In Vivo Diagnostic Substances